Salute e Benessere

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration…

Nasdaq has approved the listing of Mural Oncology's ordinary shares on the Nasdaq Global Market under the stock ticker symbol "MURA" beginning on Nov. 16, 2023. While there is no current trading market for Mural Oncology's ordinary shares, a limited "when-issued" public trading market for Mural Oncology's ordinary shares is expected to commence prior to the distribution under the stock ticker symbol "MURAV" and will continue up to and through the date of the…
PR Newswire
31/10/2023

Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2%…

Key Takeaways from the Primary Sclerosing Cholangitis Market Report Key Takeaways from the Primary Sclerosing Cholangitis Market Report Discover which therapies are expected to grab the major primary sclerosing cholangitis market share @Primary Sclerosing Cholangitis Market Report Primary Sclerosing Cholangitis Overview Primary sclerosing cholangitis (PSC) is a chronic condition that gradually damages the bile ducts. In individuals with PSC, inflammation and scarring...
PR Newswire
31/10/2023

FDA approves Novartis Cosentyx® as the first new biologic treatment option for…

FDA approval based on robust Phase III data in which Cosentyx ®(secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatment option that demonstrated reductions in inflammatory nodules and abscesses, and flares 2 HS is a chronic, progressive and often painful disease that may affect 1 in 100 people worldwide 3 ,4 Basel, October 31,...
Nasdaq GlobeNewswire
31/10/2023

Novavax's Updated COVID-19 Vaccine Now Approved in the EU

Novavax is working closely with EU member states that have requested doses through the advance purchase agreement to confirm timing of dose delivery on a country-by-country basis. Novavax is working closely with EU member states that have requested doses through the advance purchase agreement to confirm timing of dose delivery on a country-by-country basis. Approval wasbased on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses against...
PR Newswire
31/10/2023

DBV Technologies Receives Requested Feedback from FDA on Protocol Design…

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food and Drug Administration (FDA) clarifying design elements for both the COMFORT Toddlers and COMFORT Children supplemental safety studies.Both supplemental safety studies will have harmonized, simplified protocol language on how the product should be used. The COMFORT...
Nasdaq GlobeNewswire
31/10/2023

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR…

thAnnual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA). The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4 th2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.The poster is number 254 and it is entitled “ TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR...
Nasdaq GlobeNewswire
31/10/2023

ALLOSOURCE ANNOUNCES FIRST PATIENT IMPLANTATION IN UNITED KINGDOM CLINICAL…

The purpose of the UK evaluation is to assess the clinical outcomes and complications of patients undergoing cartilage surgery using ProChondrix CR as part of standard clinical care without a comparator group. ProChondrix CR is a single-stage, living cellular cartilage product that contains functional chondrocytes and other biological components necessary for the repair and replacement of damaged articular cartilage tissue.1 Created with AlloSource's proprietary cartilage cryopreservation…
PR Newswire
31/10/2023

Groupe Casino: Details of the backstopped capital increase of 275 million euros…

Details of the backstopped capital increases of 275 million euros to be implemented as part of the financial restructuring Paris, 31 October 2023Further to its press release of 5 October 2023, Casino Group announces that on 25 October 2023 at midnight (CET), the last commitment date for subscribing to the €275 million backstopped capital increases, Casino has received commitments to subscribe from the creditors for a total amount of approximately €195 million (i.e. circa 71% of the amount...
Nasdaq GlobeNewswire
31/10/2023

Sobi issues series C shares to fulfil its obligations under outstanding…

The Board of Directors has today resolved to issue 602,482 series C shares. The right to subscribe for the new series C shares shall, with deviation from the shareholders' preferential right to subscribe for shares, be granted Svenska Handelsbanken AB. The share issue will be carried out at the shares' quota value of approximately SEK 0.55 per share, and subscription for the new shares shall be made during the period 31 October - 1 November 2023. The Board of Directors also resolved, conditional…
PR Newswire
31/10/2023

Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in…

The CHMP positive opinion was based on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can…
PR Newswire
31/10/2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023

Statement of transactions in own shares from October 23 to October 27, 2023 BNP PARIBAS Aggregated presentation by day and by market Name of issuerIdentification code of issuer(Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume(in number of...
Nasdaq GlobeNewswire
31/10/2023

NTG Nordic Transport Group publishes interim report for Q3 2023

Company announcement no. 51 – 2331 October 2023 NTG Nordic Transport Group publishes interim report for Q3 2023The interim report for Q3 2023 is enclosed.In connection with publication of the results for Q3 2023, a conference call will be hosted on 1 November 2023 at 10:00 AM CET. The conference call will be held in English and can be followed live via NTG's website;investor.ntg.com.Additional information For additional information, please contact: Investor...
Nasdaq GlobeNewswire
31/10/2023

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized…

Initial EVX-01 Phase 2 data confirms the strong Phase 1 resultsAfter undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive diseaseCOPENHAGEN, Denmark, Oct.31, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology ™powered vaccines, is pleased to announce initial results from...
Nasdaq GlobeNewswire
31/10/2023

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome…

Ongoing clinical studies provide samples to the HBI's Drug Discovery Platform to validate biosynthetic NGB composition and indicate which donor's microbiome-derived components need to be isolated to create final NGB. The company announces that their proof-of-concept fecal microbiome products decolonize over 70% of ARB, and this is a great base to assume that synthetic microbiome will do the same or even better. Ongoing clinical studies provide samples to the HBI's Drug Discovery Platform to...
PR Newswire
31/10/2023

Press release Biocartis Group NV: Announcement regarding Enforcement by Secured…

PRESS RELEASE REGULATED INFORMATION 31 October 2023, 15:30 CET ANNOUNCEMENT REGARDING ENFORCEMENT BY SECURED CREDITORS The Company's Secured Creditors have enforced their security over the shares of the Biocartis operating subsidiaries Enforcement not expected to impact Biocartis's customers, suppliers, partners or employees Mechelen, Belgium, 31 October 2023– Biocartis Group NV (the “ Company ”) (Euronext Brussels: BCART) announces that it has been informed by its Secured...
Nasdaq GlobeNewswire
31/10/2023

Temperature Management Systems Market Worth $3.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141546773 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=141546773 Browse in-depth TOC on "Temperature Management Systems Market" 206 - Tables 44 - Figures 241 - Pages Temperature Management Systems Market Scope: Patient Warming Systems segment is expected to account for the largest share in 2022. The Temperature Management...
PR Newswire
31/10/2023

Coronary Artery Bypass Graft Devices Market to Reach $1.38 Billion, Globally by…

Request Sample of the Report on Coronary Artery Bypass Grafts Device Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/198433 Request Sample of the Report on Coronary Artery Bypass Grafts Device Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/198433 Coronary artery bypass graft (CABG) devices are vital instruments utilized in cardiac surgery for addressing coronary artery disease (CAD), a condition characterized by the narrowing or...
PR Newswire
31/10/2023

Surgical Equipment Market to Reach $59 Billion, Globally, by 2032 at 5.2% CAGR…

Request Sample of the Report on Surgical Equipment Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/68 Request Sample of the Report on Surgical Equipment Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/68 Surgical equipment refers to handheld tools or implements employed by healthcare professionals to carry out surgical procedures. Within an operating suite, one can find a wide array of instruments, including but not limited to...
PR Newswire
31/10/2023

BerGenBio Announces Poster Presentation at Upcoming SITC Meeting

Poster Details Poster Details Title: Bemcentinib + Pembrolizumab show promising efficacy in metastatic NSCLC patients harboring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial Poster Board Number: 598 Presentation Time: Saturday, Nov. 4, 2023 beginning at0900 Pacific Time KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,Rahway, NJ, USA Contacts Martin Olin CEO,...
PR Newswire
31/10/2023

Real World Prospective Study shows clinical implementation of Merlin Assay…

Melanoma, a highly aggressive form of skin cancer, often necessitates sentinel lymph node biopsy (SLNB) for staging, prognostication, and determining eligibility for adjuvant therapy. However, the majority of SLNB procedures do not reveal nodal metastasis, exposing patients to unnecessary surgeries and potential complications. Melanoma, a highly aggressive form of skin cancer, often necessitates sentinel lymph node biopsy (SLNB) for staging, prognostication, and determining eligibility for...
PR Newswire
31/10/2023

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia…

"Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia. GloriaBio has demonstrated a clear commitment to the motixafortide programs in stem cell mobilization and pancreatic cancer in Asia, and this transaction provides us with additional capital to continue our launch plans in the U.S.," said Philip Serlin, Chief Executive Officer of BioLineRx…
PR Newswire
31/10/2023

U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO…

The FDA defines rare pediatric diseases as rare diseases (with fewer than 200,000 cases in the United States) that are serious or life threatening and primarily affect individuals aged under 18. When the FDA awards rare pediatric disease designation (RPDD), the Sponsor of the trial firstly is granted a 6-months accelerated review of the drug candidate irrespective of indication, and which may be sold to another company. In such case the length of the approval procedure is also considerably…
PR Newswire
31/10/2023

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis…

Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis. The results can be considered by clinicians and patients when treatment decisions are being made." Dr Kessler commented, " This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on…
PR Newswire
31/10/2023

HOYA Vision Care Releases One-Year MiYOSMART European Study Results

In the eye care industry, most research on childhood myopia is being conducted in East Asia, where the condition is most prevalent.1 With myopia increasing worldwide, there is a need to test the effectiveness of myopia management solutions in children of other ethnicities and geographic areas.1 To gather the needed data, the HOYA Global Medical Affairs team began conducting a three-year observational study in the United Kingdom (UK), with the goal of extending MiYOSMART benefits to European…
PR Newswire
31/10/2023
Altri  Comunicati